The Company’s first Phase 3 trial, OnPrime (GOG-3076), will evaluate Olvi-Vec, a modified vaccinia virus, as immunochemotherapyTrial will be conducted…
Expanded facilities illustrate MaxCyte’s commitment to Montgomery County and the state of Maryland, building the life sciences community, and propelling…
ZURICH, Switzerland, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology,…
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal…
China CDE accepts Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a…
CINCINNATI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), a…
Ongoing program to focus on checkpoint inhibitor refractory patients following data presented at ASCO 2022 demonstrating 77% survival at a…
Four patents issued expanding claims related to delivery of nVNS and other therapies using mobile devicesROCKAWAY, N.J., Sept. 21, 2022…
The study evaluating a long-acting glatiramer acetate injection, GA Depot 40 mg once every four weeks, met the primary endpoint,…
Ernst & Young Orenda Corporate Finance Inc. (“EY”) engaged as independent financial advisorsTORONTO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Acerus…